CDK 4/6 Inhibitors as Single Agent in Advanced Solid Tumors-Reference-Cited by-同舟云学术

CDK 4/6 Inhibitors as Single Agent in Advanced Solid Tumors

Published:2018-12-12 Issue: Volume:8 Page:
ISSN:2234-943X
Container-title:Frontiers in Oncology
language:
Short-container-title:Front. Oncol.

Author:

Schettini Francesco,De Santo Irene,Rea Carmen G.,De Placido Pietro,Formisano Luigi,Giuliano Mario,Arpino Grazia,De Laurentiis Michelino,Puglisi Fabio,De Placido Sabino,Del Mastro Lucia

Publisher

Frontiers Media SA

Subject

Cancer Research,Oncology

Reference98 articles.

1. Cyclin D as a therapeutic target in cancer;Musgrove;Nat Rev Cancer,2011

2. Targeting CDK4/6 in patients with cancer;Hamilton;Cancer Treat Rev.,2016

3. Identifying actionable targets in advanced cancer patients: preliminary results from the Profiler program;Cassier;J Clin Oncol.,2014

4. Comprehensive molecular portraits of human breast tumors;Cancer,2012

5. High frequency of aberrant p16(INK4A) expression in human breast cancer;Geradts;Am J Pathol.,1996

Cited by 172 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost-effectiveness of early vs delayed use of abemaciclib combination therapy for patients with high-risk hormone receptor–positive/human epidermal growth factor receptor 2–negative early breast cancer;Journal of Managed Care & Specialty Pharmacy;2024-09

2. EWS-WT1 fusion isoforms establish oncogenic programs and therapeutic vulnerabilities in desmoplastic small round cell tumors;Nature Communications;2024-08-28

3. Combination of chemotherapy and endocrine treatment in breast cancer — is it still a taboo?;Oncology in Clinical Practice;2024-08-21

4. A patent review of small molecule CDK4/6 inhibitors in the treatment of cancer: 2020–present;Expert Opinion on Therapeutic Patents;2024-07-17

5. Expanding the landscape of oncogenic drivers and treatment options in acral and mucosal melanomas by targeted genomic profiling;International Journal of Cancer;2024-07-12